Under the FDA Modernization Act of 1997, Fast Track designation may potentially expedite the
review of a
drug that is intended for the treatment of a serious or life-threatening condition and that demonstrates the potential to address an unmet medical need for such a condition. The Fast Track program enables a company to file a New Drug Application (NDA) on a rolling basis.